Multi-lead Pacing for Cardiac Resynchronization Therapy in Heart Failure: a Meta-analysis of Randomized Controlled Trials

Aims: Multi-lead pacing is a potential therapy to improve response to cardiac resynchronization therapy (CRT) by providing rapid activation of the myocardium from multiple sites. Here, we perform a meta-analysis of randomized controlled trials to assess the efficacy of multi-lead pacing.

Methods And Results: A literature search was performed which identified 251 unique records. After screening, 6 studies were found to meet inclusion criteria, with 415 patients included in the meta-analysis. Four studies performed multi-lead pacing with two left ventricular (LV) leads and one right ventricular (RV) lead. One study used two RV leads and one LV lead, and one study used both configurations. There was no difference between multi-lead pacing and conventional CRT in LV end-systolic volume [mean difference (MD) -0.54 mL, = 0.93] or LV ejection fraction (MD 1.42%, = 0.40). There was a borderline significant improvement in Minnesota Living With Heart Failure Questionnaire score for multi-lead pacing vs. conventional CRT (MD -4.46, = 0.05), but the difference was not significant when only patients receiving LV-only multi-lead pacing were included (MD -3.59, = 0.25). There was also no difference between groups for 6-min walk test (MD 15.06 m, = 0.38) or New York Heart Association class at follow-up [odds ratio (OR) 1.49, = 0.24]. There was no difference in mortality between groups (OR 1.11, = 0.77).

Conclusion: This meta-analysis does not support the use of multi-lead pacing for CRT delivery. However, significant variation between studies was noted, and therefore a benefit for multi-lead pacing in select patients cannot be excluded, and further investigation may be warranted.